

Market Announcement

2 June 2022

Lumos Diagnostics Holdings Limited (ASX: LDX) – Trading Halt (2+2)

Description

The securities of Lumos Diagnostics Holdings Limited ('LDX') will be placed in trading halt at the request of LDX, pending it releasing an announcement regarding the outcome of the institutional component of the accelerated entitlement offer. Unless ASX decides otherwise, the securities will remain in trading halt until the commencement of normal trading on Wednesday, 8 June 2022.

Issued by

Alice Montefiore-King

Adviser, Listings Compliance (Sydney)



2 June 2022

Alice Montefiore-King Adviser, Listings Compliance (Sydney) ASX Compliance Pty Limited 20 Bridge Street Sydney NSW 2000

By email only: tradinghaltssydney@asx.com.au

Dear Alice,

REQUEST FOR TRADING HALT

Lumos Diagnostics Holdings Limited (ASX: **LDX**) (the **Company**) requests an immediate halt to the trading of the Company's securities (ASX: LDX) quoted on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending an announcement by the Company to the market in relation to a capital raise in the form of a pro-rata accelerated non-renounceable entitlement offer (**stated purpose**).

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

- 1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated purpose above.
- 2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on Wednesday 8 June 2022, or when an announcement regarding the stated purpose is released to the market.
- 3. The Company expects to make an announcement to the market before the commencement of normal trading on Wednesday 8 June 2022.
- 4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Yours sincerely,

Melanie Leydin Company Secretary

Lumos Diagnostics Holdings Limited